SU5416 plus interferon α in advanced renal cell carcinoma: A phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition

Vascular endothelial growth factor (VEGF) is expressed in up to 70% of renal cell carcinomas (RCCs) and is a rational therapeutic target. SU5416 is a small molecule inhibitor of VEGF-mediated signaling through Flk-1, a transmembrane tyrosine kinase. IFN-alpha also possesses dose- and schedule-depend...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2003-10, Vol.9 (13), p.4772-4781
Hauptverfasser:	LARA, Primo N, QUINN, David I, BUCKLEY, Penelope, WUN, Ted, GOSSELIN, Robert, GALVIN, Irina, GUMERLOCK, Paul H, LENZ, Heinz Josef, DOROSHOW, James H, GANDARA, David R, MARGOLIN, Kim, MEYERS, Frederick J, LONGMATE, Jeff, FRANKEL, Paul, MACK, Philip C, TURRELL, Corinne, VALK, Peter, RAO, Jyotsna
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiogenesis Inhibitors - therapeutic use Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences California Carcinoma, Renal Cell - drug therapy Cell Line, Tumor Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Disease Progression Disease-Free Survival Dose-Response Relationship, Drug Female Humans Immunotherapy - methods Indoles - therapeutic use Interferon-alpha - therapeutic use Kidney Neoplasms - drug therapy Male Medical sciences Middle Aged Neovascularization, Pathologic Pharmacology. Drug treatments Pyrroles - therapeutic use Recombinant Proteins Time Factors Tomography, Emission-Computed Treatment Outcome Vascular Endothelial Growth Factor A - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!